On 23 February 2011, orphan designation (EU/3/10/846) was granted by the European Commission to BTG plc, United Kingdom, for paclitaxel (aqueous gel) for the treatment of oesophagus carcinoma.
|Disease / condition||
Treatment of oesophagus carcinoma
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.